4282. Package #129.6 (Cervical screening extended: PAP test using liquid cytology (BD SurePath technology, FDA approved). CYTOLOGICAL PASSPORT (BD FocalPoint technology, FDA approved), p16 and Ki-67 markers, Capsid test)
Turnaround time (days): 4
4420 ₴
Important information
*FOR WOMEN ONLY
*An operator specifies the day of the menstrual cycle or the gestational age
*For the test ordering a special doctor's referral is required
Description
Package No. 129.6 is an advanced cervical screening option that combines morphological and immunochemical methods. It allows not only to detect cellular changes in the cervix but also to assess the biological activity of HPV infection and the risk of its progression.
The package includes: Pap test using BD SurePath™ liquid-based cytology with automated BD FocalPoint™ analysis (Cytology Passport) – a modern and highly accurate method for early detection of precancerous and malignant cervical changes.
At Synevo, this test is performed through a dual-expertise approach:
- by experienced cytologists;
- and with the support of an AI-based digital microscopy system – BD FocalPoint™ GS Imaging System (Becton Dickinson, USA) combined with the ZEISS Axioscope 5 microscope (Carl Zeiss, Germany).
This approach significantly increases the sensitivity and reliability of detecting pathological changes. The test helps identify epithelial cells showing signs of precancerous or malignant transformation at early stages when treatment is most effective. Markers p16 and Ki-67 are biomarkers used to assess the risk of progression of precancerous lesions. Co-expression of p16 and Ki-67 indicates a high probability of CIN2+, helping clinicians make evidence-based decisions and reducing the number of unnecessary biopsies.
Capsid test (HPV L1) – shows the phase of HPV infection:
- positive L1 → productive phase, low risk of progression;
- negative L1 → high probability of persistent infection and risk of developing CIN2+. This test allows for more accurate prediction of the disease course and helps determine whether active treatment is required or monitoring is sufficient.
When and who needs the test?
- in cases of abnormal cytological results (ASC-US, ASC-H, LSIL) with positive HPV findings;
- in HPV-positive women — to determine the appropriate management strategy;
- after CIN treatment — for monitoring the effectiveness of therapy;
- to differentiate between transient and persistent HPV infection.
Biological material
- Site-specific scrapings collected depending on the test
Preparation for cytology
- Collect the material before starting treatment with antibacterial/antifungal drugs (general and local action).
- In case of treatment monitoring – 14 days after the end of the course of treatment with antibacterial/antifungal drugs.
- Avoid sexual intercourse for 3 days.
- Exclude douching and the use of vaginal...